Johnson & Johnson EBIT Margin 2010-2023 | JNJ
Current and historical EBIT (Earnings Before Interest & Taxes) margin for Johnson & Johnson (JNJ) over the last 10 years. The current EBIT profit margin for Johnson & Johnson as of December 31, 2023 is .
Johnson & Johnson EBIT Margin Historical Data |
Date |
TTM Revenue |
TTM EBIT |
EBIT Margin |
2023-12-31 |
$85.16B |
$17.10B |
20.07% |
2023-09-30 |
$84.18B |
$15.89B |
18.88% |
2023-06-30 |
$82.82B |
$15.48B |
18.69% |
2023-03-31 |
$81.31B |
$13.94B |
17.15% |
2022-12-31 |
$79.99B |
$20.13B |
25.16% |
2022-09-30 |
$77.21B |
$18.52B |
23.99% |
2022-06-30 |
$80.55B |
$17.03B |
21.14% |
2022-03-31 |
$79.85B |
$17.80B |
22.29% |
2021-12-31 |
$78.74B |
$19.41B |
24.66% |
2021-09-30 |
$91.45B |
$19.85B |
21.71% |
2021-06-30 |
$89.19B |
$20.43B |
22.90% |
2021-03-31 |
$84.21B |
$17.72B |
21.04% |
2020-12-31 |
$82.58B |
$16.81B |
20.35% |
2020-09-30 |
$80.86B |
$19.45B |
24.05% |
2020-06-30 |
$80.50B |
$16.77B |
20.84% |
2020-03-31 |
$82.73B |
$19.98B |
24.15% |
2019-12-31 |
$82.06B |
$18.00B |
21.94% |
2019-09-30 |
$81.71B |
$17.19B |
21.04% |
2019-06-30 |
$81.33B |
$20.24B |
24.89% |
2019-03-31 |
$81.59B |
$18.38B |
22.53% |
2018-12-31 |
$81.58B |
$19.62B |
24.04% |
2018-09-30 |
$81.38B |
$18.97B |
23.30% |
2018-06-30 |
$80.68B |
$19.22B |
23.82% |
2018-03-31 |
$78.69B |
$18.95B |
24.08% |
2017-12-31 |
$76.45B |
$18.99B |
24.84% |
2017-09-30 |
$74.36B |
$20.68B |
27.81% |
2017-06-30 |
$72.53B |
$21.16B |
29.17% |
2017-03-31 |
$72.17B |
$21.26B |
29.46% |
2016-12-31 |
$71.89B |
$20.90B |
29.07% |
2016-09-30 |
$71.60B |
$20.26B |
28.30% |
2016-06-30 |
$70.88B |
$18.97B |
26.76% |
2016-03-31 |
$70.18B |
$19.68B |
28.04% |
2015-12-31 |
$70.07B |
$19.88B |
28.36% |
2015-09-30 |
$70.52B |
$18.76B |
26.61% |
2015-06-30 |
$71.88B |
$21.45B |
29.83% |
2015-03-31 |
$73.59B |
$21.32B |
28.97% |
2014-12-31 |
$74.33B |
$21.16B |
28.47% |
2014-09-30 |
$74.43B |
$21.21B |
28.49% |
2014-06-30 |
$73.54B |
$18.04B |
24.53% |
2014-03-31 |
$71.92B |
$17.20B |
23.91% |
2013-12-31 |
$71.31B |
$16.03B |
22.47% |
2013-09-30 |
$70.52B |
$16.35B |
23.19% |
2013-06-30 |
$69.99B |
$16.31B |
23.30% |
2013-03-31 |
$68.59B |
$13.57B |
19.78% |
2012-12-31 |
$67.22B |
$14.37B |
21.38% |
2012-09-30 |
$65.92B |
$11.68B |
17.72% |
2012-06-30 |
$64.87B |
$12.20B |
18.80% |
2012-03-31 |
$65.00B |
$13.58B |
20.89% |
2011-12-31 |
$65.03B |
$13.02B |
20.03% |
2011-09-30 |
$64.42B |
$14.88B |
23.09% |
2011-06-30 |
$63.40B |
$14.96B |
23.59% |
2011-03-31 |
$62.13B |
$15.75B |
25.35% |
2010-12-31 |
$61.59B |
$17.51B |
28.43% |
2010-09-30 |
$62.49B |
$17.83B |
28.53% |
2010-06-30 |
$62.59B |
$17.90B |
28.60% |
2010-03-31 |
$62.50B |
$17.94B |
28.70% |
2009-12-31 |
$61.90B |
$16.30B |
26.33% |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Large Cap Pharmaceutical |
$380.649B |
$85.159B |
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|